Evaluation of Digestive Damage and Associated Predictive Factors in Crohn's Disease 5 to 10 Years After Diagnosis (DESTIN)

July 30, 2018 updated by: Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
The primary objective is to evaluate digestive damage in CD 5 to 10 years after diagnosis in the GETAID centers included in the RAPID study. Secondary objective is to identify predictive factors of the evolution digestive damage.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Background: Crohn's disease (CD) is a chronic inflammatory disorder of the bowel that is characterized by periods of clinical remission alternating with periods of recurrence. Persistent inflammation is believed to lead to progressive bowel damage that, over time, will manifest in the development of strictures, fistulae, and abscesses. The recent development of the Lemann index allows us to precisely assess digestive damage in CD. The aim of the present study is to evaluate digestive damage and associated predictive factors in CD 5 to 10 years after diagnosis.

Methods: Prospective, multicenter, international, transversal, observational study. Patients who completed the RAPID trial (evaluating the benefits on the course of CD of an early prescription of azathioprine compared with conventional step-care therapy) will be eligible. Digestive damage will be assessed using methods described in the Lemann index protocol, dependent on CD location (abdominal MRI obligatory). The total duration of study participation for 1patient will be ≤4 months.

Aims: The primary objective is to evaluate digestive damage in CD 5 to 10 years after diagnosis in the GETAID centers included in the RAPID study. Secondary objective is to identify predictive factors of the evolution digestive damage.

Study Type

Interventional

Enrollment (Actual)

54

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Clermont-ferrand, France, 63003
        • CHU Clermont-Ferrand
      • Clichy, France, 92110
        • Hôpital Beaujon
      • Lille, France
        • CHRU Lille
      • Nice, France, 06202
        • CHU Nice
      • Paris, France, 75012
        • Hôpital Saint-Antoine
      • Paris, France, 75010
        • Hôpital Saint Louis
      • Paris, France, 75014
        • IMM
      • Pessac, France, 33700
        • CHU Bordeaux - Pessac
      • Toulouse, France, 31403
        • CHU Toulouse

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Male or female patients over 18 years old
  • Active or Inactive Crohn's Disease
  • Previously enrolled in RAPID clinical trial

Exclusion Criteria:

  • Pregnant or nursing woman
  • Patient with a contraindication or who decline to have study exams (MRI and endoscopy)
  • Other medical or psychiatric or serious chronic conditions or according to the physician's discretion that could affect the patient's cooperation or the capacity to follow study procedures.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Evaluation group

Digestive damage will be assessed on patients by using the methods described in the Lemann index protocol, dependant of Crohn's disease locations.

All patients will have clinical examination and abdominal magnetic resonance imaging analyses. Upper endoscopy, colonoscopy, and pelvic magnetic resonance imaging analyses will be performed according to disease locations :

  • Upper tract location : upper endoscopy
  • Colorectal location : colonoscopy
  • Perianal location : pelvic MRI
  • All patients : abdominal MRI
Procedure: Abdominal MRI
Abdominal MRI to realize within 4 months following inclusion
Procedure: Upper endoscopy
Upper endoscopy to realize within 4 months following inclusion
Procedure: Colonoscopy
Colonoscopy to realize within 4 months following inclusion
Procedure: Pelvic MRI
Pelvic MRI to realize within 4 months following inclusion

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Digestive damage
Time Frame: 5 to 10 years after diagnosis
Evaluate digestive damage in Crohn's Disease by using Lemann Index
5 to 10 years after diagnosis

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Predictive factors of the digestive damage evolution
Time Frame: 5 to 10 years after diagnosis
Evaluate digestive damage per organ (upper intestinal tract, small bowel, colon or rectum, anal or perianal) by using Lemann Index
5 to 10 years after diagnosis
Predictive factors of the digestive damage evolution
Time Frame: 5 to 10 years after diagnosis
Determine correlation between Lemann Index and factors measured at diagnosis and then 5 to 10 years after diagnosis.
5 to 10 years after diagnosis
Variation of Lemann Index
Time Frame: 5 to 10 years after diagnosis
Variation of Lemann Index 5 to 10 years after diagnosis
5 to 10 years after diagnosis

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

Investigators

  • Principal Investigator: Benjamin Pariente, MD, PhD, Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
  • Principal Investigator: Jacques Cosnes, MD, Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2015

Primary Completion (Actual)

February 1, 2018

Study Completion (Actual)

February 1, 2018

Study Registration Dates

First Submitted

September 11, 2015

First Submitted That Met QC Criteria

September 14, 2015

First Posted (Estimate)

September 15, 2015

Study Record Updates

Last Update Posted (Actual)

July 31, 2018

Last Update Submitted That Met QC Criteria

July 30, 2018

Last Verified

July 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2015-4

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe